Questions Circle INDs; Industry Needs Guidance For Probiotics, Say Experts
This article was originally published in The Tan Sheet
Executive Summary
FDA should consider issuing a guidance for probiotics similar to the 2004 industry guidance for botanical drugs, panelists said at a recent Drug Information Association conference
You may also be interested in...
Taiwan Biotech Touts Drug Derived From Chinese Medicine To Treat Cancer Patients
Taiwan’s Maywufa Bio Pharmaceutical Group launched a cancer-related fatigue treatment derived from an herb used in traditional Chinese medicine and plans to investigate it for cardiovascular use with clinical trials in the United States.
CAM Guidance Statement On Probiotics Is “Astonishing,” Concerns Experts
FDA's Center for Biologics Evaluation and Research may be laying the groundwork for greater control of the regulation of probiotics in the agency's recently released guidance document on "complementary and alternative medicine products," according to industry stakeholders
CAM Guidance Statement On Probiotics Is “Astonishing,” Concerns Experts
FDA's Center for Biologics Evaluation and Research may be laying the groundwork for greater control of the regulation of probiotics in the agency's recently released guidance document on "complementary and alternative medicine products," according to industry stakeholders